Decreased response to paclitaxel versus docetaxel in HER-2/neu transfected human breast cancer cells

American Journal of Clinical Oncology: Cancer Clinical Trials

Volumn 26, Issue 1, 2003, Pages 50-54

  Witters, Lois M ^a   Santala, Samuel M ^a   Engle, Linda ^a   Chinchilli, Vernon ^a   Lipton, Allan ^a,b  

^a PENN STATE COLLEGE OF MEDICINE   (United States)

^b PENN STATE MILTON S HERSHEY MEDICAL CENTER   (United States)

Author keywords

Breast cancer; Docetaxel; HER 2 neu; Paclitaxel

Indexed keywords

ANTHRACYCLINE ANTIBIOTIC AGENT; DOCETAXEL; NEU DIFFERENTIATION FACTOR; PACLITAXEL; PROTEIN BCL 2; TAXANE DERIVATIVE; TETRAZOLIUM; TRASTUZUMAB;

APOPTOSIS; ARTICLE; BREAST CANCER; CANCER HORMONE THERAPY; CELL COUNT; CLINICAL TRIAL; CONCENTRATION RESPONSE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; CYTOTOXICITY; DOSE RESPONSE; DRUG CYTOTOXICITY; DRUG EFFICACY; DRUG POTENCY; GENE OVEREXPRESSION; GENETIC TRANSFECTION; GROWTH INHIBITION; HORMONE RESISTANCE; HUMAN; HUMAN CELL; METASTASIS; ONCOGENE NEU; PHASE 2 CLINICAL TRIAL; PROTEIN INDUCTION; PROTEIN PHOSPHORYLATION; STATISTICAL SIGNIFICANCE; VECTOR CONTROL;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; BREAST NEOPLASMS; CELL DIVISION; DRUG RESISTANCE, NEOPLASM; DRUG SCREENING ASSAYS, ANTITUMOR; GENE EXPRESSION; GENES, ERBB-2; HUMANS; PACLITAXEL; TAXOIDS; TRANSFECTION; TUMOR CELLS, CULTURED;

EID: 0037321077     PISSN: 02773732     EISSN: None     Source Type: Journal    
DOI: 10.1097/00000421-200302000-00011     Document Type: Article

References (35)

1. Burris AB. Docetaxel (Taxotere) in HER-2-positive patients and in combination with trastuzumab (Herceptin). Semin Oncol 2000;27:19-23.
2. HER2 signal transduction in breast cancer cells. J Biol Chem 1991;266:14300-14305.
3. Slamon DJ, Clark GM, Wong SG, et al. Human breast cancer: correlation of relapse and survival with amplification of HER-2/neu oncogene. Science 1987;235:177-182.
4. Van de Vijver MJ, Peterse JL, Mooi WJ, et al. Neu protein overexpression in breast cancer. Association with comedo-type ductal carcinoma in situ and limited prognostic value in stage II breast cancer. N Engl J Med 1988;319:1239-1245.
5. Slamon DJ, Godolphin W, Jones LA, et al. Studies of HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 1989:244:707-712.
6. Press MF, Jones LA, Godolphin W, et al. HER-2/neu oncogene amplification and expression in breast and ovarian cancers. Prog Clin Biol Res 1990;354A:209-221.
7. Valero V, Jones SE, Von Hoff DD, et al. A phase II study of docetaxel in patients with paclitaxel-resistant metastatic breast cancer. J Clin Oncol 1998;16:3362-3368.
8. Ringel I, Horwitz SB. Studies with RPR 56976 (Taxotere): a semisynthetic analogue of Taxol. J Natl Cancer Inst 1991;83:288-291.
9. Diaz JF, Andreau JM. Assembly of purified GDP-tubulin into microtubules induced by Taxol and Taxotere: reversibility, ligand stoichiometry, and competition. Biochemistry 1993;32:2747-2755.
10. Haldar S, Basu A, Croce CM. Bcl2 is the guardian of microtubule integrity. Cancer Res 1997;57:229-233.
11. Gumerlock PH, Mack PC, Manorek GH, et al. p27 induction as a potential p53-independent mechanism of apoptotic response to taxanes in non-small cell lung cancer (NSCLC) [Abstract 723]. Proc Am Soc Clin Oncol 1999.
12. Keland LR, Abel G. Comparative in vitro cytotoxicity of Taxol and Taxotere against cisplatin-sensitive and -resistant human ovarian carcinoma cell lines. Cancer Chemother Pharmacol 1992:30:444-450.
13. Riou JF, Naudin A, Lavelle F. Effects of Taxotere on murine and human tumor cell lines. Biochem Biophys Res Commun 1992;187:164-170.
14. Nicoletti MI, Lucchini V, D'Incalci M, et al. Comparison of paclitaxel and docetaxel activity on human ovarian carcinoma xenografts. Eur J Cancer 1994;30A:691-696.
15. Vogel M, Hilsenbeck SG, Depenbrock H, et al. Preclinical activity of Taxotere (RP56976, NSC 628503) against freshly explanted clonogenic human tumour cells: comparison with Taxol and conventional antineoplastic agents. Eur J Cancer 1993;29A:2009-2014.
16. Hanauske AR, Degen D, Hilsenbeck SG, et al. Effects Taxotere and Taxol on in vitro colony formation of freshly explanted human tumor cells. Anticancer Drugs 1992;3:121-124.
17. Riou JF, Petitgenet O, Combeau C, et al. Cellular uptake and efflux of docetaxel (Taxotere) and paclitaxel (Taxol) in P388 cell line [Abstract 2292]. Proc Am Assoc Cancer Res 1994;35.
18. Valero V, Holmes FA, Walters RS, et al. Phase II trial of docetaxel: a new highly effective antineoplastic agent in the management of patients with anthracycline-resistant breast cancer. J Clin Oncol 1995;13:2886-2894.
19. Ravdin PM, Burris HA, Cook G, et al. Phase II of docetaxel in advanced anthracycline-resistant or anthracenedione-resistant breast cancer. J Clin Oncol 1995;13:2879-2885.
20. Seidman AD, Hudis CA, Raptis G, et al. Paclitaxel for breast cancer: the Memorial Sloan-Kettering Cancer Center experience. Oncology 1997;11:20-28.
21. Vermorken JB, ten Bokkel Huinink WW, Mandjes IAM, et al. High-dose paclitaxel with granulocyte colony-stimulating factor in patients with advanced breast cancer refractory to anthracycline therapy: a European Cancer Center trial. Semin Oncol 1995;22:16-22.
22. Verweij J, Clavel M, Chevallier B. Paclitaxel (Taxol) and docetaxel (Taxotere): not simply two of a kind. Ann Oncol 1994;5:495-505.
23. Chan S, Friedrichs K, Noel D, et al. Prospective randomized trial of docetaxel versus doxorubicin in patients with metastatic breast cancer. The 303 Study Group. J Clin Oncol 1999;17:2341-2354.
24. Nabholtz JM, Senn HJ, Bezwoda WR, et al. Prospective randomized trial of docetaxel versus mitomycin plus vinblastine in patients with metastatic breast cancer progressing despite previous anthracycline-containing chemotherapy. 304 Study Group. J Clin Oncol 1999;17:1413-1424.
25. Paridaens R, Biganzoli L, Bruning P, et al. Paclitaxel versus doxorubicin as first-line single agent chemotherapy for metastatic breast cancer: a European Organization for Research and Treatment of Cancer randomized study with cross-over. J Clin Oncol 2000;18:724-733.
26. Sledge GW, Neuberg D, Ingle J, et al. Phase III trial of doxorubicin (A) vs. paclitaxel (T) vs. doxorubicin + paclitaxel (A + T) as first-line therapy for metastatic breast cancer (MBC): an intergroup trial [Abstract 2]. Proc Am Soc Clin Oncol 1997.
27. Yu D, Liu B, Tan M, et al. Overexpression of c-erbB-2/neu in breast cancer cells confers increased resistance to Taxol via mdr1-independent mechanisms. Oncogene 1996;13:1359-1365.
28. Perez-Soler R, Kemp B, Wu QP, et al. Response and determinants of sensitivity to paclitaxel in human non-small cell lung cancer tumors heterotransplanted in nude mice. Clin Cancer Res 2000;6:4932-4938.
29. Baselga J, Norton L, Albanell J, et al. Recombinant humanized anti-HER2 antibody (Herceptin) enhances the antitumor activity of paclitaxel and doxorubicin against HER2/neu overexpressing human breast cancer xenografts. Cancer Res 1998;58:2825-2831.
30. Zhang L, Lau Y-K, Xia W, et al. Tyrosine kinase inhibitor emodin suppresses growth of HER-2/neu-overexpressing breast cancer cells in athymic mice and sensitizes these cells to the inhibitory effect of paclitaxel. Clin Cancer Res 1999;5:343-353.
31. Konecny G, Pegram MD, Beryt M, et al. Therapeutic advantage of chemotherapy drugs in combination with Herceptin against human breast cancer cells with HER-2/neu overexpression. San Antonio Breast Cancer Conference, 1999:Abstract 467.
32. Wiseman LR, Spencer CM. Paclitaxel: an update of its use in the treatment of metastatic breast cancer and ovarian and other gynaecological cancers. Drugs Aging 1998;12:305-334.
33. Nabholtz JM, Tonkin K, Smiylie M, et al. Chemotherapy of breast cancer: are the taxanes going to change the natural history of breast cancer? Expert Opin Pharmacother 2000;1:187-206.
34. Leitzel K, Teramoto Y, Konrad K, et al. Elevated serum c-erbB-2 antigen levels and decreased response to hormone therapy of breast cancer. J Clin Oncol 1995;13:1129-1135.
35. Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001;344:783-792.